M. J. GILL, M.B., F.R.C.P.(C); J. RUSSEL, M.B., F.R.C.P.(UK); K. BURGESS, M.B., F.R.C.P.(C); Y. H. TAN, Ph.D.
To the editor: The recent study of Shepp and colleagues (1) highlights the complex and serious nature of cytomegalovirus pneumonitis occurring in bone marrow transplant recipients. Nine of their ten patients died of the pneumonitis, despite the significant effect of their new antiviral agent on the cytomegalovirus infection. Their study shows the overall disease progressing despite the potent activity of the chemical antiviral agent against the presumed pathogen. In the past, acyclovir, vidarabine, and leukocyte (alpha) interferon, either alone or in combinations, have also proved ineffective in improving survival rates. Recently hyperimmune globulin has shown some promise in the therapy
GILL MJ, RUSSEL J, BURGESS K, TAN YH. Human Fibroblast Interferon and Acyclovir in Cytomegalovirus Pneumonia. Ann Intern Med. ;104:129–130. doi: 10.7326/0003-4819-104-1-129_2
Download citation file:
Published: Ann Intern Med. 1986;104(1):129-130.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use